ATE143267T1 - Methode zur behandlung oder verhütung von fettleibigkeit - Google Patents

Methode zur behandlung oder verhütung von fettleibigkeit

Info

Publication number
ATE143267T1
ATE143267T1 AT93925058T AT93925058T ATE143267T1 AT E143267 T1 ATE143267 T1 AT E143267T1 AT 93925058 T AT93925058 T AT 93925058T AT 93925058 T AT93925058 T AT 93925058T AT E143267 T1 ATE143267 T1 AT E143267T1
Authority
AT
Austria
Prior art keywords
preventing obesity
treating
growth hormone
effective amount
mammals
Prior art date
Application number
AT93925058T
Other languages
English (en)
Inventor
Ross G Clark
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE143267T1 publication Critical patent/ATE143267T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93925058T 1992-10-29 1993-10-26 Methode zur behandlung oder verhütung von fettleibigkeit ATE143267T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96862392A 1992-10-29 1992-10-29

Publications (1)

Publication Number Publication Date
ATE143267T1 true ATE143267T1 (de) 1996-10-15

Family

ID=25514516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93925058T ATE143267T1 (de) 1992-10-29 1993-10-26 Methode zur behandlung oder verhütung von fettleibigkeit

Country Status (13)

Country Link
EP (1) EP0669832B1 (de)
JP (1) JPH08502969A (de)
AT (1) ATE143267T1 (de)
AU (1) AU675996B2 (de)
CA (1) CA2145501C (de)
DE (1) DE69305091T2 (de)
DK (1) DK0669832T3 (de)
ES (1) ES2095086T3 (de)
GR (1) GR3022074T3 (de)
LV (1) LV11987B (de)
MD (1) MD1486G2 (de)
TJ (1) TJ286B (de)
WO (1) WO1994009813A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JPH08305892A (ja) * 1995-05-11 1996-11-22 Sega Enterp Ltd 画像処理装置及びこれを備えたゲーム装置
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP1117425A2 (de) * 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Verfahren zur behandlung von nichtthyroidstörungen
SE0000837D0 (sv) * 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
JP5108303B2 (ja) 2003-08-21 2012-12-26 テルシカ インコーポレーティッド インスリン様成長因子（ｉｇｆ−ｉ）のレベル上昇による内臓脂肪の低下方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent

Also Published As

Publication number Publication date
CA2145501A1 (en) 1994-05-11
TJ286B (en) 2000-12-13
DE69305091D1 (de) 1996-10-31
EP0669832B1 (de) 1996-09-25
JPH08502969A (ja) 1996-04-02
AU675996B2 (en) 1997-02-27
GR3022074T3 (en) 1997-03-31
ES2095086T3 (es) 1997-02-01
MD1486G2 (ro) 2001-11-30
MD960245A (en) 1997-12-31
LV11987A (lv) 1998-03-20
DK0669832T3 (da) 1997-03-17
LV11987B (en) 1998-06-20
DE69305091T2 (de) 1997-03-13
EP0669832A1 (de) 1995-09-06
AU5451294A (en) 1994-05-24
CA2145501C (en) 2004-08-10
WO1994009813A1 (en) 1994-05-11
MD1486F2 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
DK0536226T3 (de)
KR890001572A (ko) 표유동물에게 히알우론산을 원격 투여하는 방법
DE69833942D1 (de) Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
SE8703625D0 (sv) New medical use
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
DE69806246T2 (de) Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
DE69006684D1 (de) Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit.
SE8802569D0 (sv) Improvements in or relation to somatostatins
DE69305091D1 (de) Methode zur behandlung oder verhütung von fettleibigkeit
KR900003205A (ko) 제약 화합물
KR920700227A (ko) 초고활성 인체 인슐린 동족체
ATE361098T1 (de) Vorbeugung und behandlung von hypergastrinemie
JP2007119497A (ja) インターフェロン−ガンマスティミュレーター含有医薬組成物
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
Beitner et al. Prostaglandin E1 treatment of leg ulcers caused by venous or arterial incompetence
GB1474424A (en) Pharmaceutical composition for treating diabetic ketoacidosis
DE69131629T2 (de) Behandlung fehlender milchabsonderung beim menschen
EP0317933A3 (de) Behandlung von Fibromyalgie
DE69803298T2 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
RU2074715C1 (ru) Способ лечения крепитирующего тендовагинита предплечья
Schwartz The Effect of a Respiratory Enzyme on the Healing of Ulcers of the Lower Extremity: Preliminary Report

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification